Parisa Yousefpour, PhD

  • Assistant Professor of Biomedical Engineering
Profile Headshot

Overview

Parisa Yousefpour, PhD is an Assistant Professor in the Department of Biomedical Engineering. She is also a member of the Tumor Biology and Microenvironment program at the Herbert Irving Comprehensive Cancer Center (HICCC). Dr. Yousefpour designs and engineers RNA- and protein-based platforms to finely modulate immune responses, enhancing therapeutic efficacy while minimizing adverse effects. Her team develops next-generation biomolecular immunotherapies by integrating approaches from protein engineering, synthetic biology, and biomaterial science to address treatment challenges across various indications, including cancer and infectious diseases. Key research areas include engineering gene circuits for precise immunotherapy, developing controlled-release vaccine platforms, and investigating how endogenous biological mechanisms interact with biomolecular therapeutics to leverage these systems for enhanced efficacy.

Dr. Yousefpour holds a Ph.D. in Biomedical Engineering from Duke University and completed her postdoctoral training at the Massachusetts Institute of Technology.

Academic Appointments

  • Assistant Professor of Biomedical Engineering

Credentials & Experience

Education & Training

  • PhD, Biomedical Engineering, Duke University
  • Integrated BS-MS, Biotechnology/Bioprocess Engineering, University of Tehran

Honors & Awards

  • FLI (First Generation/Low Income) Student Support and Advocacy Award, Massachusetts Institute of Technology, 2024
  • Rising Stars in Engineering in Health Award, Cornell, Columbia, and John Hopkins Universities, 2023
  • Kirschstein-NRSA (F32) Postdoctoral Fellowship, National Institutes of Health, 2022-2024
  • Ludwig Postdoctoral Fellowship in Cancer Research, Massachusetts Institute of Technology, 2022
  • Convergence Scholar, Center for Precision Cancer Medicine and the Marble Center for Cancer Nanomedicine at MIT, 2020-201

Research

The Yousefpour Lab at Columbia University Irving Medical Center develops next-generation biomolecular immunotherapies by integrating approaches from protein engineering, synthetic biology, and biomaterial science to address treatment challenges across various indications, including cancer and infectious diseases. We focus on engineering RNA- and protein-based platforms to finely modulate immune responses, enhancing therapeutic efficacy while minimizing adverse effects. Our research spans the design and development of advanced biomolecular therapeutics with applications in cancer immunotherapy, vaccine development, and precision medicine. We integrate synthetic biology, biomaterials science, and immunoengineering to address key challenges in therapeutic delivery and immune modulation.

Key Research Areas:

  • Engineering RNA-Based Circuits for Tumor Microenvironment Modulation
  • Developing Controlled-release Vaccines
  • Harnessing Endogenous Mechanisms for Advanced Therapeutics